Australia, Nov. 4 -- Bristol-Myers Squibb Co., owns the trademark (2577389) for 'ADWISPO' till Aug. 14, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; antivirals; antibodies for medical purposes; biological preparations for the treatment of cancer; anticoagulants; stem cells for medical purposes; radio-pharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radio-pharmaceutical preparations; diagnostic preparations for medical purposes.] and 5 [Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease;antivirals;antibodies for medical purposes;biological preparations for the treatment of cancer;anticoagulants;stem cells for medical purposes;radio-pharmaceutical preparations for the treatment of cancer and solid tumors;diagnostic radio-pharmaceutical preparations;diagnostic preparations for medical purposes]
Type of Mark: Word
Date of Acceptance: Aug. 26
Registration Advertised: Nov. 3
For further details contact Spruson & Ferguson.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2577389.
Disclaimer: Curated by HT Syndication.
